The standard of care in HPV vaccination may soon change if a one-dose regimen is found to be just as efficacious as two or three doses—once a large trial that NCI is conducting in Costa Rica, in young women ages 12 to 16, is ready to report final results in a few years. “We’ve done […]
The phase III KEYNOTE-A18 trial, also known as ENGOT-cx11/GOG-3047, investigating Keytruda (pembrolizumab) in combination with external beam radiotherapy (EBRT) plus concurrent chemotherapy, followed by brachytherapy (also known as concurrent chemoradiotherapy) met one of its primary endpoints of progression-free survival as treatment for newly diagnosed patients with high-risk locally advanced cervical cancer.
Women with early-stage cervical cancer had significantly higher chances of developing catheter-associated urinary tract infections after radical hysterectomies if they were smokers or used a catheter for more than seven days post-surgery, UT Southwestern Medical Center researchers found in a study.
Researchers at the UNC Gillings School of Global Public Health and UNC Lineberger Comprehensive Cancer Center found mailing human papillomavirus self-collection tests and offering assistance to book in-clinic screening appointments to under-screened, low-income women improved cervical cancer screening nearly two-fold compared to scheduling assistance alone.
To mark World Cancer Day, researchers from the International Agency for Research on Cancer in collaboration with the Lalla Salma Foundation for Cancer Prevention and Treatment (Morocco) published a report that provides solutions to overcoming some of the common system-level barriers to implementation of cervical cancer screening, which are faced in many countries in sub-Saharan Africa.
A study, conducted by UC Davis Comprehensive Cancer Center researchers, shows an alarming number of California women 65 and older are facing late-stage cervical cancer diagnoses and dying from the disease, despite guidelines that recommend most women stop screening for cervical cancer at this age.
The European Commission approved Libtayo (cemiplimab) as monotherapy for the treatment of adult patients with recurrent or metastatic cervical cancer and disease progression on or after platinum-based chemotherapy.
MD Anderson Cancer Center and World Health Organization formed an agreement to establish a new international collaboration concentrated on reducing the global burden of women’s cancers. The agreement builds on years of collaboration between the two institutions to further promote their shared efforts in advancing global cancer initiatives in women’s cancers, including breast and cervical cancers.
The European Medicines Agency’s Committee for Medicinal Products for Human Use has adopted a positive opinion for Libtayo (cemiplimab) as a monotherapy for the treatment of adult patients with recurrent or metastatic cervical cancer and disease progression on or after platinum-based chemotherapy.
The European Medicines Agency’s Committee for Medicinal Products for Human Use adopted a positive opinion recommending approval of Keytruda (pembrolizumab), an anti-PD-1 therapy, in combination with chemotherapy and with or without bevacizumab, for the treatment of persistent, recurrent, or metastatic cervical cancer in adults whose tumors express PD-L1 (CPS ≥1).
